newsfilter
← Latest News
GlobeNewswire·

Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

Continues to progress Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with p53-mutated non-small cell lung cancer (NSCLC) undergoing chemotherapy Updated planned NSCLC study data readouts include interim results i